MYCO-007

MYCO-007 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.^[1]^[2]^[3]^[4]^[5] It is a short-acting MDMA analogue.^[2]^[4]^[5] MYCO-007 is being developed by Mydecine.^[1] As of February 2024, it is in preclinical research.^[1] The chemical structure of MYCO-007 does not yet appear to have been disclosed.^[1] 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) were described in Mydecine's patent for short-acting MDMA analogues^[6]^[7]^[8]

Other namesMYCO007

Drug classEntactogen; Empathogen

Quick facts Clinical data, Other names ...

MYCO-007
Clinical data
Other names	MYCO007
Drug class	Entactogen; Empathogen

References

[1]
"Delving into the Latest Updates on MYCO-007 with Synapse". synapse.patsnap.com.
[2]
"Prospectus Supplement" (PDF). Mydecine Innovations Group Inc. 15 September 2023. Retrieved 23 October 2024. MYCO - 006 and 007 represent families of molecules that are based on MDMA molecules. MYCO -006 and MYCO – 007 have been developed in order to reduce the overall acute experience time of Generation 1 MDMA by increasing the metabolism properties of the drug.
[3]
Mydecine Innovations Group (19 July 2022). "Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs". GlobeNewswire News Room. Retrieved 23 October 2024. Mydecine [...] announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been specifically designed by experts at Mydecine to have a shorter half life than traditional MDMA. The Company has named this family of novel molecules MYCO-006 and have applied for patent coverage with the World Intellectual Property Organization.
[4]
Borchardt D (17 August 2022). "Psilocybin Company Mydecine Is Down To $300k In Cash". Green Market Report. Retrieved 29 January 2025. Just last month Mydecine announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs had been specifically designed by experts at Mydecine to have a shorter half-life than traditional MDMA. The company has named this family of novel molecules MYCO-006 and applied for patent coverage with the World Intellectual Property Organization.
[5]
Dunne R (24 April 2023). "Mydecine's MDMA with rapid onset and a short duration shows promising results". Mugglehead Investment Magazine. Retrieved 29 January 2025. The effects from the company's MYCO-006 compounds last for only two hours and set in four times as fast [...] The biotech company announced the results of its preclinical mice studies on Monday examining its proprietary MDMA drug family MYCO-006. [...] MYCO-006 compounds have the same therapeutic effect as standard MDMA but have demonstrated a shorter half-life duration in animal research. The projected duration of the MYCO-006 compounds is around one to two hours, which is approximately one-third the length of the conventional six to eight hours for regular MDMA. Additionally, the onset of MYCO-006 compounds is expected to be four times faster than Gen-1 or regular MDMA. The drugs are intended to treat conditions such as PTSD, chronic pain, depression and addiction.
[6]
US 2024/0197679, Hoyer DW, Roscow RF, Ling R, Gao C, "Novel short-acting psychoactive compounds of the mdma class", published 20 June 2024, assigned to Mydecine Innovations Group Inc.
[7]
"1-(1,3-benzoxathiol-5-yl)-N-methylpropan-2-amine". PubChem. U.S. National Library of Medicine. Retrieved 23 October 2024.
[8]
"1-(1,3-benzoxathiol-5-yl)-N,N-dimethylpropan-2-amine". PubChem. U.S. National Library of Medicine. Retrieved 23 October 2024.

This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information.

See also

References

Related Articles